Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3913954

Cc1cc2oc(=O)cc(OCCCN)c2cc1C.O=C(O)C(F)(F)F

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNA3 P22001 1/20 0.40
▸ HDAC1 Q13547 2/20 0.38
▸ PPARA Q07869 2/20 0.38
▸ KDM4E B2RXH2 5/20 0.37
▸ HPGD P15428 4/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ ESR1 P03372 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ HSD17B10 Q99714 2/20 0.37
▸ GLA P06280 1/20 0.37
▸ HSP90AA1 P07900 1/20 0.37
▸ HSP90AB1 P08238 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ ALPG P10696 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ ALOX12 P18054 1/20 0.37
▸ CASP1 P29466 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3909739 0.89 KCNA3 (0.45) KCNA3HDAC1KDM4EHPGDSMN1; SMN2
Trifluoroacetic Acid SCHEMBL3911643 0.86 KCNA3 (0.44) KCNA3HDAC1PPARAKDM4EHPGD
Trifluoroacetic Acid SCHEMBL3913694 0.86 ALDH1A1 (0.44) KCNA3HDAC1PPARAKDM4EHPGD
Trifluoroacetic Acid SCHEMBL3913747 0.83 KCNA3 (0.44) KCNA3KMT2AAGERCA12CA1
Trifluoroacetic Acid SCHEMBL3914730 0.82 CYP19A1 (0.52) KCNA3HDAC1PPARAKDM4EHPGD
Trifluoroacetic Acid SCHEMBL3913777 0.82 KDM4E (0.46) KCNA3HDAC1KDM4EHPGDSMN1; SMN2
Trifluoroacetic Acid SCHEMBL3922171 0.82 PIM1 (0.44) KCNA3HDAC1KDM4EHSD17B10CA12
Trifluoroacetic Acid SCHEMBL3913356 0.82 HTR2C (0.45) KCNA3PPARAKDM4EHPGDALDH1A1
Trifluoroacetic Acid SCHEMBL3923252 0.79 KCNA3 (0.46) KCNA3PPARAALDH1A1HTR2CCA12
Trifluoroacetic Acid SCHEMBL3925125 0.78 KCNA3 (0.45) KCNA3HDAC1PPARAALDH1A1HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538233-B2 Coumarins as iNOS inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2009-05-26 — — US disclosed
EP-1667988-A1 COUMARINS AS INOS INHIBITORS Aventis Pharmaceuticals Inc. (US) 2006-06-14 — — EP disclosed
WO-2005026143-A1 COUMARINS AS INOS INHIBITORS AVENTIS PHARMACEUTICALS INC. (US) 2005-03-24 — — WO disclosed
US-20050054681-A1 Coumarins as iNOS inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2005-03-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054681-A1 Coumarins as iNOS inhibitors NOS2, NOS1, NOS3 KCNA3 3807/4885HDAC1 389/4885PPARA 3606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback